劉媛博士自2019年1月起擔(dān)任本公司疫苗研究負(fù)責(zé)人，主要負(fù)責(zé)疫苗佐劑的研發(fā)工作。其研究領(lǐng)域涵蓋鼠兔乙型肝炎疫苗、人鼠兔狂犬病疫苗，以及正在開(kāi)發(fā)的新型佐劑型腫瘤疫苗。在此之前，劉博士于2014年7月至2019年1月期間任職于益生興業(yè)研發(fā)部，并2019年1月份起任益生興業(yè)研究部副總裁。她專注于疫苗佐劑研究已超過(guò)十年，且在2016年獲得北京市優(yōu)秀人才培養(yǎng)基金青年骨干個(gè)人項(xiàng)目資助。

劉博士于 2008 年 7 月獲中山大學(xué)學(xué)士學(xué)位，2014 年 7 月在中國(guó)科學(xué)院大學(xué)獲得博士學(xué)位。

Head of Vaccine Research

Dr. Yuan Liu has served as our head of vaccine research since January 2019. She is responsible for the R&D of vaccine adjuvants, including PIKA hepatitis B vaccine, human PIKA rabies vaccine, and new adjuvant-based tumor vaccine under development.

Dr. Liu served as project leader of the R&D department at YS Group Xingye from July 2014 to January 2019 and has served as vice president of the research department at YS Group Xingye since January 2019. She has focused on the research of vaccine adjuvants for over 10 years. In 2016, she received the sponsorship of the Young Backbone Individual Project from the Beijing Outstanding Talent Training Fund.

Dr. Liu received her Ph.D. degree in University of Chinese Academy of Sciences in July 2014. She received her bachelor’s degree in Sun Yat-sen University in July 2008.